CytoReason and the Crohn's & Colitis Foundation Forge Groundbreaking Data Collaboration to Advance IBD Research
Integrating the Foundation's IBD Plexus® real-world data platform into CytoReason's computational disease models to accelerate discovery in inflammatory bowel disease.
TEL AVIV (May 16, 2024) - CytoReason, a pioneer in developing computational disease models for drug development, today announced a strategic collaboration with the Crohn’s & Colitis Foundation. The collaboration aims to empower CytoReason’s analytical capabilities with the Foundation’s IBD Plexus® real-world data platform. This collaboration has the potential to accelerate new discoveries with superior data integration and improve the precision and effectiveness of drug development in inflammatory bowel disease (IBD).
As part of the collaboration, the Foundation’s IBD Plexus® real-world data platform, comprising thousands of patient intestinal biopsies and comprehensive real-world data, will be integrated into CytoReason’s pre-computed disease model platform. The combination of IBD Plexus® real-world data with CytoReason’s advanced computational capabilities will enable fine characterization of disease subtypes, positioning of treatments and combination therapies throughout disease subtypes, and generation of blood-based biomarkers to facilitate clinical trials. In addition, the collaboration will enable characterizing the molecular trajectory of natural disease courses and differential drug effects, which promises to deepen the IBD field’s understanding and treatment of these diseases by leveraging AI and large-scale molecular and clinical datasets.
"This partnership with the Foundation is not just a milestone for CytoReason but a leap forward for the entire industry. By integrating the Foundation’s vast datasets into our models, we can provide deeper insights into IBD, and enable the development of more targeted and effective therapies."
Prof. Yehuda Chowers, Chief Medical Officer, CytoReason"Informing CytoReason’s computational models with extensive real-world data from IBD Plexus® allows us to deepen our understanding of IBD at a molecular level and explore new pathways for potential therapies. This collaboration underscores the power of combining rich clinical and molecular data with innovative algorithms to potentially deliver more targeted and effective treatments for patients suffering from IBD."
Dr. Alan Moss, Chief Scientific Officer, Crohn’s & Colitis FoundationAbout CytoReason
CytoReason is a technology company transforming biopharma's decision-making from trial and error to data-driven, using computational disease models for predictive asset insights. Therapeutic area leaders, research teams, and scientists of all levels rely on CytoReason's technology to increase the speed and accuracy of R&D decisions. Backed by strategic investors such as NVIDIA, Thermo Fisher Scientific, and Pfizer, CytoReason's technology is used by top pharma companies across the globe. Learn more at www.cytoreason.com.
About the Crohn's & Colitis Foundation
The Crohn's & Colitis Foundation is the leading nonprofit organization focused on both research and patient support for inflammatory bowel disease (IBD), with the mission of curing Crohn's disease and ulcerative colitis and improving the quality of life for the millions of people living with IBD. The Foundation's work is dramatically accelerating the research process, while also providing extensive educational and support resources for patients and their families, medical professionals, and the public. To learn more about the IBD Plexus® program, visit crohnscolitisfoundation.org.